N/A N=106 FlowTriever Pulmonary Embolectomy Clinical Study
Pulmonary Embolism · Acute Pulmonary Embolism · Submassive Pulmonary Embolism
Primary: Change in RV/LV Ratio — 0.38 RV/LV ratio — p=< 0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,538 Age of Blood in Children in Pediatric Intensive Care Units
Anemia
Primary: Number of Participants With New or Progressive Multiple Organ Dysfunction Syndrome (NPMODS) — 147; 133 Participants
N/A N=30 NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation
Mitral Valve Failure
Primary: Number of Participants With "Acceptable" Technical Success of the LAMPOON Procedure — 30; 30; 30; 30 participants
N/A N=340 Healthy Hearts Healthy Minds
Cardiovascular Diseases · Depression
Primary: Change (Per Day) in Average Daily Steps From Baseline — 2.8; 2.9; -8.2; -1.2 Change (per day) in Average Daily Steps — p=0.973
N/A N=39 A Novel Approach for Thyroplasty Type 1, With Prolene Mesh. A Prospective Study.
Vocal Cord Paralysis · Phonasthenia · Presbylarynges
Primary: Change in Mean Phonation Time — 7.74; 14.08 seconds
Phase 2 N=150 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Masseter Muscle Prominence
Primary: Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90 as Assessed by the Investigator — 21.7; 90.6; 91.3 percentage of…
Phase 1 N=76 H1N1v Virus Challenge Study in Healthy Subjects
Influenza
Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…
N/A N=75 A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)
Chronic Rhinosinusitis (Diagnosis)
Primary: Randomized Cohort: Difference in Patency Grade of FSO — 1.6; 1.5 score on a scale
Phase 2 N=26 Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis
Pouchitis · Ulcerative Colitis
Primary: Clinical Remission — 4; 5 Participants — p=0.183
N/A N=122 Smoking Cessation in Menthol Flavored Cigarette Smokers
Tobacco Use Disorder
Primary: Time to Lapse — 1.07; 2.55 days
Phase 2 N=12 Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
Chronic Hepatitis C
Primary: Number of Subjects With Treatment Emergent Adverse Events — 10 Participants
Phase 1 N=25 Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects
Type 2 Diabetes Mellitus
Primary: Cmax (Maximum Observed Plasma Concentration) — 176.1; 133.7 ng/mL
Phase 3 N=160 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001
Phase 3 N=131 Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
HIV Infections
Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) Regardless of Antiretroviral…
Early Phase 1 N=6 Intranasal Heparin Tolerability Study
Covid19
Primary: Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1 — 6; 0 Participants